Is Tesamorelin safe? What do clinical trials show

Clinical trials generally indicate that tesamorelin is relatively safe and well-tolerated when used under appropriate medical supervision, although it may cause adverse effects, increase IGF-1 levels, and may not be suitable for individuals with certain medical conditions [1–11].

Clinical trials have consistently shown that tesamorelin effectively reduces visceral abdominal fat while maintaining an acceptable safety profile. In a randomized, placebo-controlled trial conducted by Falutz et al. (2007), tesamorelin reduced visceral fat by approximately 15% over 26 weeks without a significant deterioration in fasting glucose levels or insulin regulation [1]. Similar results were reported in pooled Phase III studies conducted by Falutz et al. (2010), where tesamorelin continued to reduce abdominal fat and improve lipid markers while remaining generally well-tolerated [2]. Long-term extension studies also demonstrated that continuing tesamorelin therapy for up to 52 weeks maintained the benefits without the emergence of new serious safety concerns during treatment [3].

Research into HIV-associated nonalcoholic fatty liver disease (NAFLD) has also shown encouraging safety outcomes. Stanley et al. (2019) found that tesamorelin significantly reduced liver fat over 12 months with no significant differences in fasting glucose or HbA1c compared to placebo [4]. HbA1c is a blood test reflecting average blood sugar levels over several months. Fourman et al. (2020) further reported improvements in liver mitochondrial function and inflammatory pathways without evidence of hepatotoxicity [5]. These findings are relevant as tesamorelin acts via the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) pathway, which can impact metabolism and cell growth signaling.

The most frequently reported adverse events with tesamorelin in clinical trials included:

• Injection site reactions
• joint pain (arthralgia)
• muscle pain (myalgia)
• mild swelling or water retention
• peripheral edema (fluid accumulation in tissues)
• tingling or numbness (paresthesia)
• mild hypersensitivity reactions or allergic reactions [1–4,6,7]

Most adverse events were described as mild to moderate, not severe. Injection site reactions were among the most common complaints, as tesamorelin is administered daily as a subcutaneous injection, meaning an injection into the fatty tissue under the skin [1-3].

Tesamorelin can significantly increase IGF-1 levels, which is a major part of the drug's mechanism of action. Many clinical studies have consistently shown elevated IGF-1 levels during treatment [1,2,8]. Since persistently high IGF-1 levels can theoretically affect pathways related to cancer or metabolic regulation, regular monitoring of IGF-1 levels is often recommended during therapy.

The impact on blood glucose levels was also thoroughly examined during tesamorelin treatment. Most studies showed generally stable fasting glucose levels and HbA1c, although a portion of participants exhibited slight increases in glucose-related markers [4,6,9]. Rahman et al. (2023) observed a mild increase in HbA1c in some participant groups during post-hoc analyses of phase III trials, but the changes were typically minor [6]. Current evidence suggests that tesamorelin may have a more favorable glycemic profile compared to direct growth hormone therapy, as it stimulates the body's natural pulsatile GH secretion rather than continuous exogenous growth hormone delivery.

Certain individuals may not be suitable candidates for tesamorelin therapy. Typical contraindications and precautions include:

• active cancer
• pregnancy
• known allergy or hypersensitivity to tesamorelin or its ingredients
• significant hypothalamic-pituitary disorders
• Pituitary tumors or previous pituitary surgery
• severe uncontrolled endocrine disorders

Additional caution is also often recommended for individuals with diabetes risk factors, glucose intolerance, or a history of cancer, as tesamorelin affects GH and IGF-1 signaling pathways [10].

Long-term safety data for tesamorelin remain relatively promising, although studies outside of HIV-related conditions are still quite limited. Falutz et al. (2008) demonstrated sustained visceral fat reduction for 52 weeks with generally acceptable tolerability [3]. A more recent meta-analysis by Badran et al. (2026) of randomized controlled trials found that tesamorelin improved body composition, reduced liver fat, and increased lean body mass without causing severe adverse events or significant glucose metabolism disturbances [11]. However, researchers noted a higher incidence of joint pain, muscle pain, paresthesia, and injection site reactions compared to placebo.

Generally speaking, current clinical evidence suggests tesamorelin is generally safe with appropriate prescribing and medical monitoring, particularly for HIV-associated visceral fat accumulation and fatty liver disease. However, because tesamorelin impacts hormonal pathways related to GH and IGF-1, thorough screening, monitoring, and individualized medical assessment remain important during treatment.

Disclaimer

The content is for educational and scientific informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is a prescription medication that affects hormonal pathways and may not be suitable for everyone. Tesamorelin should only be used under the supervision of a qualified healthcare professional with appropriate metabolic and endocrinological health monitoring.

References

1. Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
2. Falutz J, Mamputu, J. C., Potvin, D., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
3. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058
4. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
5. Fourman LT, Billingsley, J. M., Agyapong, G., et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 5(16), e140134. https://doi.org/10.1172/jci.insight.140134
6. Rahman F, McLaughlin, T., Mesquita, P., et al. (2023). Effect of Tesamorelin in People With HIV With and Without Dorsocervical Fat: Post Hoc Analysis of a Phase III Double-Blind Placebo-Controlled Trial. Journal of Clinical and Translational Science, 7(1), e40. https://doi.org/10.1017/cts.2022.515
7. Russian SC, Ockene, M. W., Arpante, A. K., et al. (2024). Efficacy and safety of tesamorelin in people with HIV taking integrase inhibitors. AIDS, 38(12), 1758–1764. https://doi.org/10.1097/QAD.0000000000003965
8. Falutz J, Allas, S., Kotler, D., et al. (2005). Placebo-controlled dose-ranging study of a growth hormone-releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS, 19(12), 1279–1287. https://doi.org/10.1097/01.aids.0000180099.35146.30
9. Baker LD, Barsness, S. M., Borson, S., et al. (2012). Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: Results of a controlled study. Archives of Neurology, 69(11), 1420–1429. https://doi.org/10.1001/archneurol.2012.1970
10. Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (2018). Tesamorelin. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: NCBI Tesamorelin Overview
11. Badran AS, Helal, A., Shata, K. S., & Ayesh, H. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice, 20(1), 2–12. https://doi.org/10.1016/j.orcp.2026.01.002